Efficacy of Adalimumab Therapy for Non-Infectious Uveitis in Japanese Patients: Methotrexate Concomitance Across Different Uveitis Etiologies and the Effect of Dose Spacing.

Adalimumab reduced systemic corticosteroid dosage (mean 13.7 mg/day at baseline to 0.9 mg/day at 12 months; Wilcoxon signed-rank test p < 0.0001 for baseline-to-12-month change) and improved best-corrected visual acuity (mixed-effects model: p = 0.035 at 12 months) and inflammation markers.

Patients with late- or chronic-stage Vogt-Koyanagi-Harada disease/sympathetic ophthalmia showed a trend toward a higher requirement for methotrexate concomitance than Behçet's disease patient.

Over half of the 24 patients attempting dose spacing relapsed (14/24), but disease control was regained by shortening intervals.